ISRCTN90296187进行中（未招募）2 期
An open-label, randomised, phase 2 study of rituximab as adjunctive therapy in the treatment of Burkitt’s lymphoma at QECH, Blantyre, Malawi
niversity of Malawi College of Medicine0 个研究点目标入组 220 人开始时间: 2016年6月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Child <14 yrs of age with proven Burkitt's lymphoma (BL) or relapse or resistant BL
- •2. After full information, the guardians have given written informed consent, and the child if appropriate will be asked for assent
- •3. The guardian and patient will be willing and able to complete treatment and follow-up
排除标准
- •1. Patients known to be allergic to trial medications
- •2. Patients or their guardians who do not consent
- •3. Pregnant and/or breastfeeding patients
研究者
相似试验
进行中（未招募）
不适用
Open-labeled, multicenter phase II study of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) chemotherapy in patients with non-conjunctival ocular adnexal MALT lymphoma.KCT0003048The Catholic University of Korea, Seoul St. Mary's Hospital33
招募中
不适用
A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with Waldenström´s macroglobulinemiaKCT0003255Kosin University Gospel Hospital54
进行中（未招募）
不适用
An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2006-001985-17-DEEli Lilly and Company limited61
进行中（未招募）
1 期
An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma - N/Ahigh-risk diffuse large B-cell lymphoma (DLBCL )MedDRA version: 8.1Level: LLTClassification code 10012822Term: Diffuse large B-cell lymphoma refractoryEUCTR2006-001985-17-FREli Lilly and Company limited61
进行中（未招募）
1 期
A Phase 2 Study of Ruxolitinib in Combination With Pemetrexed/Cisplatin and for Treatment of Subjects With Advanced Lung Canceronsquamous NSCLC that is Stage IIIB, Stage IV, or recurrentMedDRA version: 18.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001436-10-PTIncyte Corporation156